Latest news with #FlatironHealth
Business Wire
7 days ago
- Business
- Business Wire
Flatiron Health Triples Global Oncology Research Network, Unlocking Multinational Evidence Generation
NEW YORK--(BUSINESS WIRE)--Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data (RWD), today announced that its international oncology research network has tripled in size across the UK, Germany, and Japan over the past year—a milestone that marks an unprecedented acceleration in global cancer research collaboration and impact. In just five years, Flatiron established a global network of more than 30 leading academic medical centers, hospitals, universities, and community sites across Europe and Japan that contribute deidentified patient data to Flatiron's real-world database. Share Flatiron Health entered international markets to address the growing unmet need for high-quality, real-world oncology data that is reflective and representative of patient populations, practice patterns, and care settings globally. In just five years, Flatiron established a global network of more than 30 leading academic medical centers, hospitals, universities, and community sites across Europe and Japan that contribute deidentified patient data to Flatiron's real-world database. Notable partners include Leeds Teaching Hospitals NHS Trust, University Hospitals Of Leicester NHS Trust, and Newcastle Hospitals NHS Foundation Trust in the UK; Klinikum Stuttgart in Germany; and the National Cancer Center Hospital East, National Cancer Center Hospital, Nagoya University Hospital, Aichi Cancer Center Hospital, Institute of Science Tokyo Hospital in Japan. Furthermore, Flatiron also supports a broader group of data users to maximize the generation of impactful evidence, such as its collaboration with University Hospital Essen in Germany, where Flatiron multinational RWD was used for research published in Nature Cancer and presented at ASCO GU. "The unprecedented expansion of our global network will continue to support improvements to local cancer patients' care and novel multinational research—fundamentally changing what's possible for our partners and the patients they serve," said Nathan Hubbard, Chief Business Officer at Flatiron Health. 'Our partners are already unlocking answers to complex research questions—answers that traditional data sources can't support. By leveraging this expanded real-world evidence, which spans from understanding standards of care and treatment patterns to informing HTA and regulatory decisions, this momentum is improving cancer care for patients worldwide.' Flatiron has authored seven research studies incorporating its multinational RWD within the past two years powered by Flatiron's Trusted Research Environment (TRE) (Powered by Lifebit CloudOS)—a secure platform that enables access to patient-level data at scale. In research published in E SMO Real World Data and Digital Oncology, Flatiron Health researchers, software engineers, and medical oncologists local to each geography came together to characterize oncology RWD in the UK, Germany, and Japan. The work demonstrated how Flatiron's TRE enables cross-country cohort analyses, while maintaining local data control and compliance. The methods and approach described in this paper enable global researchers with the tools to investigate treatment patterns and outcomes across diverse healthcare systems, fostering high-quality, multinational evidence generation. 'Flatiron is committed to building research cohorts that are reflective and representative of the real-world oncology populations and local care standards,' said Hideaki Bando, MD, Chief, Division of Drug and Diagnostic Development Promotion at National Cancer Center Hospital East. 'Increased understanding of how different cancers impact different geographical areas is critical to generate robust evidence to inform targeted treatment strategies worldwide.' While Flatiron's international oncology network marks significant progress in enabling robust research across these regions, many countries outside the UK, Germany, and Japan still lack access to locally-available oncology datasets that are representative, methodologically sound, and recent enough for research needs. To help address these remaining gaps, Flatiron established Flatiron FORUM (Fostering Oncology RWE Uses and Methods), a global consortium that brings together biopharma and academic partners to collaboratively advance a portfolio of research studies focused on the transportability of oncology data across borders. Through Flatiron FORUM, participants co-develop concrete use cases, apply new methodologies, and rigorously validate the transportability of outcomes between regions and diverse healthcare systems—including countries beyond the UK, Germany, and Japan. This collaborative approach addresses critical challenges in regulatory science and access, ultimately supporting better evidence generation and improved outcomes for patients worldwide. 'Flatiron's real-world data is a powerful complement to the UK's cancer registries, adding new clinical depth and recency that help fill critical evidence gaps,' said Prof. Geoff Hall, Professor of Cancer Medicine & Digital Health and Consultant Oncologist at Leeds Teaching Hospitals NHS Trust, UK. 'Through the combined strength of Flatiron's global oncology research network and Flatiron FORUM, we are unlocking richer insights for both local innovation and multinational research—ultimately supporting more informed clinical breakthroughs, regulatory decisions, and better outcomes for patients across the UK and worldwide.' Flatiron is committed to expanding research access to increasingly representative oncology patient cohorts across the UK, Germany, and Japan, complementing its already extensive US cohorts. This expansion supports a growing set of use cases for researchers, clinicians, and policymakers to answer critical questions about cancer care—driving the next era of global oncology research. For more information about Flatiron's global network and research initiatives, visit Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. @FlatironHealth
Yahoo
10-06-2025
- Business
- Yahoo
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development
Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) ('Day One' or the 'Company'), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). 'We are thrilled to welcome Mike during this pivotal time at Day One. As an accomplished biopharmaceutical executive with more than 25 years of experience in building businesses and leading teams in oncology therapeutic development, commercialization and health technology, Mike will be an outstanding addition to our leadership team,' said Jeremy Bender, Ph.D., chief executive officer of Day One. 'Mike will be instrumental in supporting our ongoing medical and scientific strategies to drive OJEMDA's growth while also continuing to build our pipeline of first- or best-in-class medicines for patients of all ages with life-threatening diseases.' As Head of R&D and a member of the Executive Leadership Team, the Company's research, development and medical affairs infrastructure will report to Dr. Vasconcelles. Dr. Vasconcelles' experience spans more than 25 years in oncology research and development as an academic hematologist/oncologist and as an industry leader at both large pharmaceutical and emerging biotechnology companies. Most recently, he was the Executive Vice President and Head of Research, Development, and Medical Affairs at ImmunoGen. He was instrumental in transforming the company from primarily a clinical development and U.S.-focused commercial stage organization to a vertically integrated, global biotech enterprise. This transformation was accomplished through reinvestment in ImmunoGen's research infrastructure, and the globalization of product launch and lifecycle management investment to optimize the commercialization of ELAHERE® (mirvetuximab soravtansine-gynx). Prior to ImmunoGen, he served as Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a subsidiary of the Roche Group. Prior to Flatiron Health, Dr. Vasconcelles was Chief Medical Officer at Unum Therapeutics after leading the Oncology Therapy Area Unit at Takeda for several years. Earlier in his career, he oversaw the clinical development of Genzyme's transplant and oncology portfolio as Group Vice President and Global Therapeutic Area Head of Transplant and Oncology. Following Sanofi's acquisition of Genzyme, he led Personalized Medicine and Companion Diagnostics at Sanofi Oncology. 'I'm excited to join Day One at such a critical moment in its growth. The company has been built on a bold vision to deliver transformative therapies for children with cancer and is extending its unwavering commitment to scientific excellence into this new chapter with its vision of bringing transformative medicines to patients of all ages. Having previously developed medicines for childhood leukemia, Day One's vision deeply resonates with me,' said Michael Vasconcelles, M.D. 'I look forward to supporting OJEMDA, advancing the existing pipeline, and expanding the portfolio, working with the team to lead the organization through its next stage of growth, and impact.' In addition to Dr. Vasconcelles' new role as Head of Research and Development at Day One, he continues to serve as an Independent Director at Kura Oncology Inc. and Molecular Partners AG. Dr. Vasconcelles earned both his B.A., and M.D., from Northwestern University, where he serves on the Executive Committee of the Medical Alumni Association for the Feinberg School of Medicine. During the period from 1996-2021, Dr. Vasconcelles held a faculty appointment at the Harvard Medical School, where he completed all of his postgraduate training, and was an associate physician at the Beth Israel Hospital, the Brigham and Women's Hospital and the Dana-Farber Cancer Institute. About Day One Biopharmaceuticals Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by 'The Day One Talk' that physicians have with patients and their families about an initial cancer diagnosis and treatment plan, Day One aims to re-envision cancer drug development and redefine what's possible for all people living with cancer—regardless of age—starting from day one. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company's pipeline includes tovorafenib (OJEMDA™) and DAY301. Day One is based in Brisbane, California. For more information, please visit or find the Company on LinkedIn or X. Day One uses its Investor Relations website ( its X handle ( and LinkedIn Home Page ( as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Cautionary Note Regarding Forward-Looking StatementsThis press release contains 'forward-looking' statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Day One's plans to develop and commercialize cancer therapies, expectations from current and planned clinical trials, the execution of the Phase 2 and Phase 3 clinical trial for tovorafenib as designed, expectations with respect to the timing of Day One's Phase 1a/b clinical trial of DAY301, any expectations about safety, efficacy, timing and ability to complete clinical trials, release data results and to obtain regulatory approvals for tovorafenib and other candidates in development, and the ability of tovorafenib to treat pLGG or related indications. Statements including words such as 'believe,' 'plan,' 'continue,' 'expect,' 'will,' 'develop,' 'signal,' 'potential,' or 'ongoing' and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause Day One's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties in this press release and other risks set forth in our filings with the Securities and Exchange Commission, including Day One's ability to develop, obtain and retain regulatory approval for or commercialize any product candidate, Day One's ability to protect intellectual property, the potential impact of global business or macroeconomic conditions, including as a result of inflation, changing interest rates, cybersecurity incidents, significant political or regulatory developments or changes in trade policy, including tariffs or shifting priorities within the U.S. Food and Drug Administration, global regional conflicts and the sufficiency of Day One's cash, cash equivalents and investments to fund its operations. These forward-looking statements speak only as of the date hereof and Day One specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law. DAY ONE MEDIALaura Cooper, Head of Communicationsmedia@ DAY ONE INVESTORSLifeSci Advisors, PJ Kelleherpkelleher@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share The updated release reads: FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025 Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research. Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Yahoo
22-05-2025
- Business
- Yahoo
CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025
Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research. NEW YORK, May 22, 2025--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." The updated release reads: FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025 Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research. Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, "Driving Knowledge to Action: Building a Better Future," by delivering critical evidence to inform and improve patient care. "AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution," said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. "Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer." Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Abstracts and Poster PresentationsRacial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC) Catherine Keane, Gene G. Ho, Samantha Reiss, Melissa Estevez, Katherine Harrison, Anca Marinescu, Olive MbahBreast Cancer—MetastaticPoster board: 63Abstract number: 1084 Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC) Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. CohenBreast Cancer—Local/Regional/AdjuvantPoster board: 148Abstract number: 555 Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status Partners: Memorial Sloan Kettering Cancer Center, AstraZenecaDana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan LiGenitourinary—Prostate, Testicular, and PenilePoster board: 295Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at AnschutzMaureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav GoyalQuality Care/Health Services ResearchPoster board: 436Abstract number: 11097 Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of ChicagoJay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya JulooriLung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic CancersPoster board: 199Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer CenterMajd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. MeropolTherapeutics—Molecularly Targeted Agents and Tumor BiologyPoster board: 486bAbstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. RyalsOnline publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood SpecialistsAnosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. BataviaOnline publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: IncyteKim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela MunteanuOnline publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo ClinicJennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. ParikhOnline publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD SeronoAmanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark GuinterOnline publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: GenentechQianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly MageeOnline publication only Real-world progression-free survival of CDK4/6 inhibitors (CDK4/6i) plus an aromatase inhibitor (AI) in HR+/HER2− MBC in US routine clinical practice Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer CenterHope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam BrufskyOnline publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer CenterMark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias JabbourOnline publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. View source version on Contacts Nina Toorpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Business
- Business Wire
Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen Breast Cancer—Local/Regional/Adjuvant Poster board: 148 Abstract number: 555 Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
